Back to Search
Start Over
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single‐arm, open‐label, phase 3 trial
- Source :
- Journal of Gastroenterology and Hepatology
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Background and Aim This single‐arm, open‐label, multicenter, phase 3 trial evaluated the efficacy and safety of seraprevir, an hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic HCV infection without cirrhosis. Methods Treatment‐naive or interferon‐experienced adult patients without cirrhosis were treated with a universal, combinational regimen of seraprevir 100 mg, twice daily and sofosbuvir 400 mg, once daily, for 12 or 24 weeks. The primary efficacy endpoint was sustained virologic response at week 12 after treatment (SVR12). Results Overall, 205 patients with genotype 1 HCV infection without cirrhosis were enrolled from 23 sites, 202 of whom completed the full treatment and post‐treatment course and 3 discontinued follow‐up. In total, 27 patients (13.2%) were interferon experienced. SVR12 was achieved by 201 out of 205 (98.0% [95% CI, 95.1%, 99.5%]) patients, 100.0% of patients with genotype 1a, and 98.0% of genotype 1b. In the other exploratory study, SVR 12 was achieved by 100% patients with genotype 2 (n = 21), genotype 3 (n = 7), and genotype 6 (n = 8). The majority of adverse events were mild to moderate and transient and did not require a specific medical intervention. Conclusions The all‐oral, ribavirin‐free regimen of seraprevir and sofosbuvir is an effective and well‐tolerated treatment option for Chinese patients mono‐infected with HCV, including those with a history of interferon treatment.
- Subjects :
- safety
Adult
Liver Cirrhosis
China
medicine.medical_specialty
Cirrhosis
Genotype
Sofosbuvir
Hepatitis C virus
Hepacivirus
Viral Nonstructural Proteins
Clinical Trials and Therapeutics
medicine.disease_cause
sofosbuvir
Antiviral Agents
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Interferon
Internal medicine
medicine
Humans
Adverse effect
Hepatology
business.industry
sustained virologic response
Hepatitis C
Hepatitis C, Chronic
medicine.disease
Regimen
Treatment Outcome
030220 oncology & carcinogenesis
seraprevir
Drug Therapy, Combination
030211 gastroenterology & hepatology
hepatitis C
business
medicine.drug
Subjects
Details
- ISSN :
- 14401746 and 08159319
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Gastroenterology and Hepatology
- Accession number :
- edsair.doi.dedup.....06583ad003b9f33c8d63bf61e7958ed9